Modulation of the Neuro–Cancer Connection by Metabolites of Gut Microbiota

Biomolecules, Journal Year: 2025, Volume and Issue: 15(2), P. 270 - 270

Published: Feb. 12, 2025

The gut-brain-cancer axis represents a novel and intricate connection between the gut microbiota, neurobiology, cancer progression. Recent advances have accentuated significant role of microbiota metabolites in modulating systemic processes that influence both brain health tumorigenesis. This paper explores emerging concept metabolite-mediated modulation within connection, focusing on key such as short-chain fatty acids (SCFAs), tryptophan derivatives, secondary bile acids, lipopolysaccharides (LPS). While microbiota's impact immune regulation, neuroinflammation, tumor development is well established, gaps remain grasping how specific contribute to neuro-cancer interactions. We discuss with potential implications for neurobiology cancer, indoles polyamines, which yet be extensively studied. Furthermore, we review preclinical clinical evidence linking dysbiosis, altered metabolite profiles, tumors, showcasing limitations research gaps, particularly human longitudinal studies. Case studies investigating microbiota-based interventions, including dietary changes, fecal transplantation, probiotics, demonstrate promise but also indicate hurdles translating these findings therapies. concludes call standardized multi-omics approaches bi-directional frameworks integrating microbiome, neuroscience, oncology develop personalized therapeutic strategies patients.

Language: Английский

---

Advances in understanding therapeutic mechanisms of probiotics in cancer management, with special emphasis on breast cancer: a comprehensive review

European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 177410 - 177410

Published: Feb. 1, 2025

Language: Английский

---

Operationalizing Team Science at the Academic Cancer Center Network to Unveil the Structure and Function of the Gut Microbiome

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(6), P. 2040 - 2040

Published: March 17, 2025

Oncologists increasingly recognize the microbiome as an important facilitator of health well a contributor to disease, including, specifically, cancer. Our knowledge etiologies, mechanisms, and modulation states that ameliorate or promote cancer continues evolve. The progressive refinement adoption “omic” technologies (genomics, transcriptomics, proteomics, metabolomics) utilization advanced computational methods accelerate this evolution. academic center network, with its immediate access extensive, multidisciplinary expertise scientific resources, has potential catalyze research. Here, we review our current understanding role gut in prevention, predisposition, response therapy. We underscore promise operationalizing network uncover structure function microbiome; highlight unique microbiome-related expert resources available at City Hope Comprehensive Cancer Center example team science achieve novel clinical discovery.

Language: Английский

---

Editorial: Gut microbiota and gastrointestinal disorders, volume II

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12

Published: March 17, 2025

The human gut microbiota, an intricate ecosystem of bacteria, viruses, fungi, and archaea, plays a pivotal role in maintaining gastrointestinal (GI) homeostasis (1). Recent advancements microbiome research have unveiled its profound influence on various GI disorders, including gastric cancer, inflammatory bowel disease (IBD), irritable syndrome (IBS), acute pancreatitis, Clostridioides difficile infection (CDI) (2). Understanding the interplay between microbiota these disorders offers promising avenues for novel therapeutic interventions, next-generation probiotics, fecal transplantation (FMT), targeted microbiome-oriented modulation (3,4).Gastric cancer remains significant global health burden, ranking as fourth leading cause cancer-related mortality. Dysbiosis, characterized by altered microbial diversity composition, is hallmark carcinogenesis (Marashi et al.). Helicobacter pylori wellestablished risk factor, yet eradication alone does not fully restore equilibrium. Studies suggest that certain bacterial species, such Lactobacillus, enhance immunotherapy responses, whereas antibiotic-induced dysbiosis can reduce efficacy chemotherapy al.) (5,6). Probiotic supplementation post-gastrectomy has demonstrated potential mitigating inflammation fostering healthier milieu (7). IBD, encompassing Crohn's ulcerative colitis, immune-mediated disorder driven complex genetic, environmental, factors (Ning (8). Dysbiosis relationship metabolic functions extends beyond tract. Emerging explored bidirectional connection insulin-like growth factor 1 (IGF-1), key regulator growth-related pathways (Zheng been implicated modulating IGF-1 levels, suggesting consequences imbalances. This insight broadens scope microbiome-targeted therapies to include alongside diseases.The expanding knowledge underscores need precision medicine approaches. Personalized profiling could guide tailored optimizing outcomes. Probiotics, prebiotics, synbiotics, nextgeneration microbiome-based therapies, engineered consortia postbiotics, offer exciting prospects. Moreover, metagenomics metabolomics will further elucidate host-microbe interactions, paving way strategies (13).In conclusion, published studies this Research Topic highlight integral determinant disease. From IBS multifaceted (Stange Harnessing interventions holds immense revolutionizing management, shifting from symptomatic treatment root-cause (14). As continues unravel complexities future gastroenterology lies leveraging microscopic powerhouse transformative healthcare solutions.

Language: Английский

---

Assessing the impact of probiotics on immunotherapy effectiveness and antibiotic-mediated resistance in cancer: a systematic review and meta-analysis

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 21, 2025

Background Probiotics have been demonstrated to exert a potential clinical enhancing effect in cancer patients receiving immune checkpoint inhibitors (ICIs), while antibiotics detrimental impact. Prior meta-analysis papers substantial limitations and are devoid of recent published studies. Therefore, this study aimed perform an updated and, for the first time, assess whether probiotics can restore damage immunotherapy. Methods A comprehensive literature search was conducted three English databases Chinese with cutoff date August 11, 2024. The methodological quality studies evaluated using Newcastle-Ottawa Quality Assessment Scale (NOS) or Revised Cochrane risk-of-bias tool (RoB 2). Engauge Digitizer v12.1 employed extract hazard ratios (HRs) 95% confidence interval (CI) survival outcomes when these data were not explicitly provided manuscripts. Meta-analysis Stata 14 software. Results sample comprised eight retrospective four prospective studies, involving total 3,142 participants. findings indicate that significantly prolong overall (OS) (I 2 = 31.2%; HR=0.58, CI: 0.46-0.73, p < 0.001) progression-free (PFS) 65.2%; HR=0.66, 0.54-0.81, ICIs, enhance objective response rate (ORR) 33.5%; OR=1.75, 1.27-2.40, disease control (DCR) 50.0%; OR=1.93, 1.11-3.35, 0.002). For non-small cell lung (NSCLC) exposed antibiotics, use associated superior OS 0.0%; HR=0.45, 0.34-0.59, PFS HR=0.48, 0.38-0.62, compared non-users. Subgroup differences observed regarding type (P=0.006) ethnic backgrounds (P=0.011) OS. Conclusions suggest effectively extend treated ICIs. In NSCLC, appear mitigate negative impact on immunotherapy effectiveness, which has profound significance. Nevertheless, additional large-scale, high-quality randomized controlled trials necessary further validate findings. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=579047 , identifier CRD42024579047.

Language: Английский

---

The cancer microbiome

Advances in clinical chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Modulation of gut microbiota by probiotics to improve the efficacy of immunotherapy in hepatocellular carcinoma

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 22, 2024

Hepatocellular carcinoma, a common malignancy of the digestive system, typically progresses through sequence hepatitis, liver fibrosis, cirrhosis and ultimately, tumor. The interaction between gut microbiota, portal venous system biliary tract, referred to as gut-liver axis, is crucial in understanding mechanisms that contribute progression hepatocellular carcinoma. Mechanisms implicated include dysbiosis, alterations microbial metabolites increased intestinal barrier permeability. Imbalances or contributes carcinoma by producing carcinogenic substances, disrupting balance immune altering metabolic processes, increasing Concurrently, accumulating evidence suggests microbiota has ability modulate antitumor responses affect efficacy cancer immunotherapies. As new effective strategy, immunotherapy offers significant potential for managing advanced stages with checkpoint inhibitors achieving advancements improving patients' survival. Probiotics play vital role promoting health preventing diseases modulating inflammation responses. Research indicates they are instrumental boosting modulation microbiota. This review explore relationship emergence assess contributions probiotics outline latest research findings, providing safer more cost-effective strategy prevention management

Language: Английский

---

Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes?

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(18), P. 10120 - 10120

Published: Sept. 20, 2024

Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by enhancing anti-tumour immune responses, demonstrating significant efficacy in various malignancies, including melanoma. However, over 50% of patients experience limited or no response to ICI therapy. Resistance ICIs is influenced a complex interplay tumour intrinsic and extrinsic factors. This review summarizes current for melanoma the factors involved resistance treatment. We also discuss emerging evidence that microbiota can impact outcomes modulating biology function. Furthermore, profiles may offer non-invasive method predicting response. Therefore, future research into manipulation could provide cost-effective strategies enhance improve patients.

Language: Английский

---

Adipose-Derived Stromal Cells and Cancer-Associated Fibroblasts: Interactions and Implications in Tumor Progression

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(21), P. 11558 - 11558

Published: Oct. 28, 2024

Adipose-derived stromal cells (ASCs) and cancer-associated fibroblasts (CAFs) play pivotal roles in the tumor microenvironment (TME), significantly influencing cancer progression metastasis. This review explores plasticity of ASCs, which can transdifferentiate into CAFs under influence tumor-derived signals, thus enhancing their secretion extracellular matrix components pro-inflammatory cytokines that promote tumorigenesis. We discuss critical process epithelial-to-mesenchymal transition (EMT) facilitated by ASCs CAFs, highlighting its implications for increased invasiveness therapeutic resistance cells. Key signaling pathways, including transforming growth factor-β (TGF-β), Wnt/β-catenin, Notch, are examined regulating EMT CAF activation. Furthermore, we address impact epigenetic modifications on ASC functionality, emphasizing recent advances targeting these to inhibit pro-tumorigenic effects. also considers metabolic reprogramming supports tumor-promoting activities through enhanced glycolytic activity lactate production. Finally, outline potential strategies aimed at disrupting interactions between cells, targeted inhibitors key pathways innovative immunotherapy approaches. By understanding complex within TME, this aims identify new opportunities could improve patient outcomes treatment.

Language: Английский

---

OncoSexome: the landscape of sex-based differences in oncologic diseases

Nucleic Acids Research, Journal Year: 2024, Volume and Issue: 53(D1), P. D1443 - D1459

Published: Nov. 13, 2024

The NIH policy on sex as biological variable (SABV) emphasized the importance of sex-based differences in precision oncology. Over 50% clinically actionable oncology genes are sex-biased, indicating drug efficacy. Research has identified non-reproductive cancers, highlighting need for comprehensive cancer data. We therefore developed OncoSexome, a multidimensional knowledge base describing (https://idrblab.org/OncoSexome/) across four key topics: antineoplastic drugs and responses (SDR), oncology-related biomarkers (SBM), risk factors (SRF) microbial landscape (SML). SDR covers 2051 anticancer drugs; SBM describes 12 551 sex-differential biomarkers; SRF illustrates 350 sex-dependent factors; SML demonstrates 1386 microbes with abundances associated development. OncoSexome is unique illuminating multifaceted influences cancer, providing both external endogenous contributors to development broadest oncological classes. Given increasing global research interest differences, expected impact future practices significantly.

Language: Английский

---